SpiroChem welcomes a New Member on its Board of Directors.

Dr. Anthony D. Baxter, PhD

Dr. Anthony Baxter is a serial entrepreneur and past CEO of several successful science-based CROs: Cyprotex plc, sold (2016) to Evotec (58 mio £) | Argenta Discovery, sold (2014) to CRL (30 mio £). He has held C-level and Chairman posts at Oxford Asymmetry Ltd, sold (2000) to Evotec (360 mio £), deltaDOT Ltd, Glythera Ltd, DNAmeIT Ltd amongst others. Before becoming an entrepreneur, Tony worked as a medicinal chemist with 13 years senior level experience with GSK (1983-1990) and Ciba-Geigy UK (now Novartis, 1990-1995). Tony graduated from the University of Manchester in Salford, UK (MSc, PhD)